期刊文献+

艾滋病患者抗艾滋病毒治疗免疫学和病毒学失败情况分析 被引量:5

Study on the Immunological and virologic failure in HIV/AIDS patients with highly active antiretroviral therapy
原文传递
导出
摘要 目的了解河北省艾滋病患者抗病毒治疗过程中病毒学失败和免疫学失败情况,为开展二线药物治疗工作提供依据。方法对河北省接受免费抗病毒治疗的病人进行免疫学和病毒学随访检测,分析其病毒学失败率,免疫学失败率和相关影响因素。结果 63例病人中免疫学失败率为46.03%,病毒学失败率为58.73%,免疫学和病毒学均失败率33.33%。结论各级卫生部门应加强对艾滋病病人的随访和耐药检测,通过及时优化治疗方案、提高病人服药依从性等措施,进一步提高抗病毒治疗效果。 Abstract: Objective To analyze the situation of immunological and virologic failure in HIV/AIDS patients with highly active antiretroviral therapy (HAART)treatment,and to provide data base for analyzing the effect of HAART. Methods The rates of immunological failure and virologic failure and the influencing factors were aulyzed by means of the detection of patients'CD4 cell count and HIV-1 viral load in Hebei province. Results The rate of Immunological failure was 46.03% and, the rate of virologic failure was 58.73% and the rate of the mmunological and virologic failure was 33.33% among 63 patients with HIV-1. Conclusions The local health administration department at different levels should strengthen the follow-up and the drug-resistance dection of HIV-l-infectedpatients,and through improving treatment regime and increasing adherence support, the effect of HAART will be further improved.
出处 《中国热带医学》 CAS 2013年第10期1214-1216,共3页 China Tropical Medicine
基金 河北省科学技术研究与发展计划(No.08276101D-92)
关键词 关键词 人类免疫缺陷病毒I型 病毒学失败 免疫学失败 抗病毒治疗 Key words :Human immunodeficiency virus-l Immunological failure Virologic failure Antiviral therapy
  • 相关文献

参考文献12

  • 1张福杰.国家免费艾滋病抗病毒药物治疗手册[M].第2版.北京:人民卫生出版社,2008:98-99.
  • 2Brenda C, Angelina V, Arturo G, et al. Effectiveness of highly active antiretroviral therapy (HAART)among HIV- infected patients in Mexico[J]. AIDS Res Hum Retroviruses,2010,26(4):373-388.
  • 3宋春鑫,危剑安,孙利民,周伟,黄霞珍,陈宇霞,金燕.国内艾滋病的免疫学研究进展[J].中医研究,2005,18(8):56-58. 被引量:7
  • 4柏雪莲,张珍,刘克义.人类免疫缺陷病毒感染的免疫学(英文)[J].中国热带医学,2005,5(9):1935-1938. 被引量:3
  • 5Ma Y,Zhao D,Dou Z,et al. Predictors of virologic failure in HIV-1- infected adults receiving f'ast-line antiretroviral therapy in 8 provinces in China[J]. Clin Infect Dis,2010,50(2):264-271.
  • 6Zhang F,Dou Z,Ma Y,et al . Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV- related mortality in China: a national observational cohort study[J] . Lancet Infect Dis,2011,11(7) :516-524.
  • 7Fielding KL',Charalambous S,Stensen AL,et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study [J]. BMC Infect Dis, 2008,8 : 93-94.
  • 8Wang X,L Yang,H Li,et al. Factors Associated with HIV Virologic Failure Among Patients on HAART for one Year at Three Sentinel Surveillance Sites in China [J] . Curr HIV Res,2011,9 (2): 103- 111.
  • 9李韩平,李宏,杨坤,王哲,鲍作义,辛天义,庄道民,李敬云.河南省部分艾滋病患者抗病毒治疗的临床效果以及基因型耐药性分析[J].中华微生物学和免疫学杂志,2005,25(3):194-198. 被引量:49
  • 10崔为国,豆智慧,刘佳,孙国清,王水旺,王超峰,范二军,王哲,赵德才.河南三个重点县HIV/AIDS抗病毒治疗者病毒学失败率横断面研究[J].中华实验和临床感染病杂志(电子版),2012,6(1):4-8. 被引量:11

二级参考文献40

  • 1张春迎,陈军,郑煜煌,雷建华,周华英,张永红,何艳,罗开忠,蒋永芳,欧秋英,黄竹林.艾滋病患者高效抗逆转录病毒治疗两年的效果和副作用[J].中华内科杂志,2006,45(6):494-496. 被引量:33
  • 2Moroni M. Genotypic resistance tests for the management of patients with vitro-immunological disordant response to highly active antireoviral therapy. Scand J Infect Dis Suppl, 2003, 106: 85-87.
  • 3Puro V. Genotypic resistance tests for the management of post exposure prophylaxis. Scand J Infect Dis Suppl, 2003, 106: 93-98.
  • 4杰伊A利维.艾滋病病毒与艾滋病的发病机制[M].北京:科学出版社,2000.282-303.
  • 5Maga G, Hübscher U, Pregnolato M, et al. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and D-and-L-(β)-dideoxynucleoside T tiphosphae analogs. Antimicrobial Agents and Chemotherapy, 2001, 45(4 ): 1192-1200.
  • 6de Ronde A, van Dooren M, van der Hoek L, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol, 2001, 75(2): 591-602.
  • 7Eric J, Miguel E, Quiňones-Mateu, et al. 3′-azdio-3′-deoxythymidine(AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human iImmunodeficiency virus type 1 variants. J Virol, 1998, 72 (6): 4858-4865.
  • 8Van der Vliet H J, von Blomberg BM, Hazenberg MD, et al. Selec-tive decrease in circulating V alpha 24 + V beta 11 + NK T cells during HIV type 1 infection [ J ]. J Immunol, 2002, 168:1490-1495.
  • 9Schwarz M, Wells TN, Proudfoot AE. Chenokine receptors-the next thera-peutic target for HIV [ J ] ? Receptors Channels, 2001,7:417-428.
  • 10Grundner C,Li Y,Louder M,et al.Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins[J].Virology.2005 Jan 5; 331(1):33~46.

共引文献89

同被引文献37

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部